EVAX — Evaxion Biotech A/S
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: DK
- Exchange: NASDAQ Capital Market
- Employees: 46
- Website: https://evaxion.ai
Latest SEC filings for EVAX
- 6-K — 2026-10-23
- 6-K — 2026-10-19
- 6-K — 2026-10-02
- 6-K — 2026-09-14
- 6-K — 2026-09-04
- 6-K — 2026-08-20
- 6-K — 2026-08-20
- 6-K — 2026-08-17
- 6-K — 2026-08-14
- 6-K — 2026-07-17
Latest EVAX news
- — Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting (GlobeNewswire Inc.)
Educational tool only — not investment advice.